STAT+: Definium Therapeutics says its LSD therapy eased anxiety in late-stage trial

Results mark second major win for company in the past two months Mario Tama/Getty Images Jason is a general assignment reporter, with particular focus on genetic medicine and rare disease. Confidential tips can be sent on Signal at JasonMast.77. Definium Therapeutics said Wednesday that its LSD therapy significantly helped patients with generalized anxiety disorder in the first of two large trials. It’s the second major win for Definium in the past two months, following a Phase 3 success in major depression. In the Phase 3 anxiety study, 214 patients were randomly assigned to receive a single dose of DT120 — Definium “proprietary, pharmaceutically optimized” LSD pill — or a placebo. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+. Already have an account? Log in View All Plans To read the rest of this story subscribe to STAT+. Subscribe General Assignment Reporter Jason is a general assignment reporter, with particular focus on genetic medicine and rare disease. Confidential tips can be sent on Signal at JasonMast.77.